ArticleInternational journal of epidemiology2025
Analgesic opioids in pregnancy and placental malperfusion-related disorders: a population-based cohort study.
Article in International journal of epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAnalgesic opioid use in pregnancy could increase the risk of disorders related to placental malperfusion, but this relationship is incompletely characterized. We aimed to study the causal association between analgesic opioids in pregnancy and placental abruption, pre-eclampsia, preterm birth, and fetal growth restriction (FGR).
methodsWe conducted a population-based cohort study of pregnancies resulting in birth at ≥20 weeks of gestation between July 2013 and December 2019 in New South Wales, Australia. Linked data on pregnancy, births, medication dispensation, and health services were used. Opioid exposure was defined as at least one opioid dispensation from the last menstrual period to birth. We stratified analyses by exposure in early (≤20 weeks) and/or late (>20 weeks) pregnancy and opioid type by using non-exposed pregnancies as a comparator. We estimated risks by using Cox proportional-hazards models and time-varying exposure, adjusting for demographics, comorbidities, and other medications.
resultsAmong 509 971 births, 32 266 (6.3%) had an opioid dispensation. We observed modestly increased risks with any opioid exposure for placental abruption [adjusted hazard ratio (HR) 1.22, 95% confidence interval (CI) 1.06-1.41] and preterm birth (adjusted HR 1.23, 95% CI 1.18-1.28), but not for pre-eclampsia (adjusted HR 1.06, 95% CI 0.99-1.13) or FGR (adjusted HR 0.95, 95% CI 0.88-1.02). Risks of abruption were the most elevated when exposure occurred in both early and late pregnancy (adjusted HR 1.76, 95% CI 1.30-2.40) and for preterm birth when exposure occurred in late-only pregnancy (adjusted HR 1.36, 95% CI 1.27-1.45). Monotherapy with both codeine and oxycodone was associated with elevated risks of abruption and preterm birth.
conclusionIn this population-based cohort study, we observed modestly increased risks of preterm birth and placental abruption after analgesic opioid use in pregnancy, driven by codeine and oxycodone-the two most frequently used opioids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.